All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1100+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

AstraZeneca’s Fasenra nabs EU approval for rare immune-mediated vasculitis, second indication after 2018’s severe eosinophilic asthma nod
Monoclonal antibody, eosinophilic granulomatosis with polyangiitis, vasculitis - Read more

Eli Lilly’s GLP-1 golden goose Mounjaro nabs Hong Kong Department of Health approval for comorbidities with obesity
GLP-1, obesity, type 2 diabetes - Read more 

THE GOOD
Business Development

Novartis pays Monte Rosa Therapeutics $150M upfront, $2.1B biobucks for “molecular glue degraders”, focused on Ph1 asset MRT-6160
Molecular glue degrader, systemic autoimmune, neurological autoimmune - Read more

HOPO Therapeutics nabs $226M BARDA contract to development HOPO-101 for radioactive heavy metal poisoning
Small molecule, radioactive heavy metal poisoning - Read more

Wuxi AppTec still signing new clients despite Biosecure threats
CDMO, manufacturing, Biosecure Act - Read more

Aardvark Therapeutics buys ME-344 asset from MEI Pharma for $500k upfront, $62M biobucks
Small molecule, solid tumor - Read more [Press release in Korean]

THE GOOD
Clinical Trials

Johnson & Johnson showcases positive Ph3 data for Tremfya in Crohn’s disease
Monoclonal antibody, Crohn’s disease - Read more

Eli Lilly, not to be outdone, also posts positive Ph3 data Crohn’s disease, but with their asset mirikizumab, with additional data in ulcerative colitis
Monoclonal antibody, Crohn’s disease, ulcerative colitis - Read more

Today is a duelling day, as Novartis and Apellis also drop competing, positive Ph3 data for iptacopan and pegcetacoplan respectively, in rare kidney disease
Small molecule, C3 glomerulopathy, primary immune complex membranoproliferative glomerulonephritis, kidney disease - Read more

Biogen touts positive Ph2 data for felzartamab in treating IgA nephropathy
Monoclonal antibody, IgA nephropathy, kidney disease - Read more

Vera Therapeutics’ atacicept may be a “functional cure” to IgA nephropathy as Ph2b trial touts effects lasting at least 96 weeks
Recombinant fusion protein, IgA nephropathy - Read more

EyePoint Pharmaceuticals makes a clinical comeback with “high quality” Ph2 data for Duravyu in diabetic macular edema
Small molecule, diabetic macular edema, drug-device combo, sustained release - Read more

Corxel Pharmaceuticals, LENZ Therapeutics tout positive data for LNZ1000 eye drops treating presbyopia in China Ph3 trial
Small molecule, prebyopia - Read more

Celldex Therapeutics’ barzolvolimab sticks Ph2 landing with positive data in two forms of chronic inducible urticaria (hives)
Monoclonal antibody, chronic inducible urticaria, cold urticaria, symptomatic dermographism, hives) - Read more

Ironwood Pharmaceuticals comes back with Ph3 data subset for apraglutide in short bowel syndrome in attempt to woo investors
Peptide, GLP-2, short bowel syndrome - Read more

PRESENTED BY YOU?
Get the attention of 1100+ Biotech & Pharma Professionals 🤩

Looking to promote your biotech/pharma/life science-focused product or service to a captivated audience of industry professionals?

Consider sponsoring TLDR Biotech - your sponsored feature would go right here! Check out our prospectus for more details.

And if you’re ready to work with us, just reply to this email or message me on LinkedIn.

⬇️ More Good News ⬇️

THE GOOD
Company Launches

Ottimo Pharma launches with undisclosed raise and an “exquisitely designed” lead asset in jankistomig
Bifunctional antibody, solid tumor, cancer - Read more

Kivu Biosciences launches with $92M Series A and “kinder, gentler ADC” tech from Synaffix
Antibody-drug conjugates, cancer - Read more

THE GOOD
Fundraises

Resalis Therapeutics “strategic” equity financing from Sanofi, undisclosed amount, funds to develop obesity hopeful RES-010
Antisense oligonucleotide, obesity - Read more

Starget Pharma $5.1M raise from Cancer Focus Fund
Radiopharm, cancer, precision peptide radioligand - Read more

ProQR Therapeutics Public Offering, Private Placement combined gross proceeds of $63M
RNA, cholestatic diseases, cardiovascular disease - Read more

THE GOOD
Mergers & Acquisitions

AbbVie buys Aliada Therapeutics for $1.4B cash, acquires both tech that helps meds pass-through the blood-brain barrier and an early stage Alzheimer’s asset
Amyloid beta antibody, Alzheimer’s disease, platform technology, blood-brain barrier, drug delivery - Read more

THE GOOD
Partnerships

Odyssey Therapeutics, Terray Therapeutics collab on discovery, development of “First-in-Class” transcription factor therapies
Small molecule, drug discovery, drug development - Read more

GC Biopharma, Novelty Nobility joint R&D partnership for novel geographic atrophy treatments
Antibody-based therapies, geographic atrophy, age-related macular degeneration, drug discovery - Read more

Eli Lilly, ViaNautis Bio strategic collab to leverage nanovesicle platform for genetic medicine delivery
Drug delivery, nanovesicles, genetic medicines - Read more

Bristol Myers Squibb, chemistry lab at University of Texas at San Antonio research collab to find more “green” pharma manufacturing-relevant catalysts
Pharma manufacturing, green chemistry - Read more

THE GOOD
Strategic Plans

FogPharma rebrands to Parabilis Medicines, aims to incorporate AI into "every aspect of the discovery and development process"
Small molecule, colorectal cancer, solid tumor, AI - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Approvals & Labels

Astellas withdraws Izervay approval application in Europe after regulator discussions, though “remains confident” in future prospects
RNA, geographic atrophy, small molecule - Read more

PharmaTher handed CRL by FDA for racemix ketamine (Ketarx)
Small molecule, psychiatric disorder, patch - Read more

THE BAD
Earnings & Finances

CombiGene conducts the dreaded “strategic evaluation”, cost-cutting planned and discontinues CG01 epilepsy program
Gene therapy, epilepsy, AAV - Read more

THE BAD
Politics & Policy

US bipartisan scrutiny comes down on FDA for perceived “narrow” criteria for what is an “active ingredient” in awarding priority review vouchers
Priority review vouchers - Read more [Paywall]

THE UGLY
Opinions

I’m here for the drama; Prime Medicine CSO publicly calls out Tessera Therapeutics during European Society of Cell and Gene Therapy annual meeting
Gene editing - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here